Inhibiting pulmonary metastasis of breast cancer based on dual-targeting graphene oxide with high stability and drug loading capacity

Li, Jing; Liang, Xiao; Zhang, Jun; Yin, Yuchen; Zuo, Teng; Wang, Yiyue; Yang, Xiaoming; Shen, Qi

doi:10.1016/j.nano.2018.02.012

Cited by 31 publications

(22 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For delivery purposes, GO presents a high surface area, aspect ratio and cell internationalization ability that fulfil important requirements for an excellent nanocarrier platform. Indeed, in a combinatorial strategy suggested by Li et al 80 , GO was covalently linked to polyethylenimine with the purpose of anchoring two materials (folate and heparin) able to specifically recognize breast cancer cells. The composite was also loaded with doxorubicin, a well-known chemotherapy medication, via π-π and hydrophobic interactions.…”

Section: Gbm In Therapeutic Strategiesmentioning

confidence: 99%

Do biomedical engineers dream of graphene sheets?

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Gbm In Therapeutic Strategiesmentioning

confidence: 99%

Do biomedical engineers dream of graphene sheets?

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Covalent binding of PEG to GO has been widely used to improve the stability and long circulation of GO with high drug-loading capacity [13,14]. GO modified by antibodies or peptides or other bioactive molecules could achieve targeted delivery [15][16][17]. Though GO-based nanocarriers feature a number of advantages over other nanocarriers, they are restricted by their poor drug-release capacity.…”

Section: Introductionmentioning

confidence: 99%

Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

et al. 2020

View full text Add to dashboard Cite

Background: Enzalutamide (Enz) has shown limited bioavailability via oral administration. Castration-resistant prostate cancer (CRPC) is frequent among patients receiving 18-24 months of androgen deprivation therapy. The nonsteroidal anti-androgen enzalutamide (Enz) used in the treatment of prostate cancer has shown limited bioavailability via oral administration. Therefore, we developed a multifunctional enzalutamide-loaded graphene oxide nanosystem (TP-GQDss/Enz) for CRPC intravenous treatment, with high drug loading efficiency. Methods: Aminated graphene quantum dots (GQDs) were first cross-linked via disulfide bonds into a graphene quantum dot derivative of approximately 200 nm (GQDss), which was further functionalized with a tumour-targeting peptide and PEG to form TP-GQDss. Enz was loaded into TP-GQDss for in vitro and in vivo study. Results: The results showed that high drug-loading efficiency was achieved by TP-GQDss via π-π electron interaction. TP-GQDss could be rapidly internalized by CRPC cells via endocytosis. Moreover, Enz in TP-GQDss could inhibit the growth of C4-2B and LNCaP prostate cancer cell lines in vitro. Further, TP-GQDss exhibited an enhanced cancertargeting ability and alleviated the side effects of Enz in vivo. Conclusions: The multifunctional nanocarrier constructed here could accomplish controlled Enz release and serve as an intravenous therapy platform for CRPC.

show abstract

“…Covalent binding of PEG to GO has been widely used to improve the stability and long circulation of GO with high drug-loading capacity [13,14]. GO modified by antibodies or other bioactive molecules or peptides could achieve targeted delivery [15,16,17]. Though GO-based nanocarriers feature a number of advantages over other nanocarriers, they are restricted by their poor drug-release capacity.…”

Section: Introductionmentioning

confidence: 99%

Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

Jiang

Chen

Gong

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Enzalutamide (Enz) has shown limited bioavailability via oral administration. It is easy for patients to develop into castration-resistant prostate cancer (CRPC) due to resistance to 18-24 months of androgen deprivation therapy (ADT). Moreover, it is hard to delivery Enz in vivo for low drug loading (DL) and encapsulation efficiency (EE).Therefore, we developed a multifunctional enzalutamide-loaded graphene oxide nanosystem (TP-GQDss/Enz) for castration-resistant prostate cancer (CRPC) intravenous treatment, with high drug loading efficiency.Methods: Aminated graphene quantum dots (GQDs) were first cross-linked via disulfide bonds into a graphene quantum dot derivative of approximately 200 nm (GQDss), which was further functionalized with a tumour-targeting peptide and PEG to form TP-GQDss. Enz was loaded into TP-GQDss for in vitro and in vivo study.Results: The results showed that high drug-loading efficiency was achieved by TP-GQDss via π-π electron interaction. TP-GQDss could be rapidly internalized by CRPC cells via endocytosis. Moreover, Enz in TP-GQDss could promote the inhibition of cell growth in vitro against CRPC cells. Further, TP-GQDss exhibited an enhanced cancer-targeting ability and alleviated the side effects of Enz in vivo. Conclusions: The multifunctional nanocarrier constructed here could accomplish controlled Enz release and serve as an intravenous therapy platform for CRPC.

show abstract

Inhibiting pulmonary metastasis of breast cancer based on dual-targeting graphene oxide with high stability and drug loading capacity

Cited by 31 publications

References 42 publications

Do biomedical engineers dream of graphene sheets?

Do biomedical engineers dream of graphene sheets?

Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy

Contact Info

Product

Resources

About